Sentinel seroprevalence of SARS-CoV-2 in Gauteng Province, South Africa, August - October 2020
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.04.27.21256099: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics approval: The study was approved by the University of the Witwatersrand Human Ethics Committee (certificate number M2008105). Sex as a biological variable We reported sex as male and female. Randomization Samples selection: We randomly selected remnant samples received at the Chemistry departments from Charlotte Maxeke Johannesburg Academic (CMJAH) Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory methods: Anti-SARS CoV-2 antibody testing was performed on the Roche Cobas™ e604 analyser utilising the Roche Elecsys™ SARS-CoV2 chemiluminescent assay (both Roche Diagnostics, Mannheim, Germany). Anti-SARS CoV-2suggested: NoneThe assay … SciScore for 10.1101/2021.04.27.21256099: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Ethics approval: The study was approved by the University of the Witwatersrand Human Ethics Committee (certificate number M2008105). Sex as a biological variable We reported sex as male and female. Randomization Samples selection: We randomly selected remnant samples received at the Chemistry departments from Charlotte Maxeke Johannesburg Academic (CMJAH) Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Laboratory methods: Anti-SARS CoV-2 antibody testing was performed on the Roche Cobas™ e604 analyser utilising the Roche Elecsys™ SARS-CoV2 chemiluminescent assay (both Roche Diagnostics, Mannheim, Germany). Anti-SARS CoV-2suggested: NoneThe assay measures total antibodies targeting the nucleocapsid (N) protein of the coronavirus with higher affinity for IgM and IgG antibodies. IgGsuggested: NoneSoftware and Algorithms Sentences Resources Statistical analysis: Data were captured on Microsoft Excel spreadsheet and analysis was performed in Stata statistical software (Stata Corp, College Station, TX, USA). Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of this study is that we do not have any data from private laboratories which serve a different, wealthier population. Patient comorbidities were considered as an individual predictor of antibody production. In HIV infected individuals (PWH) where data were available, seropositivity correlated significantly with improved immune reconstitution. This is suggestive that HIV-infected individuals are able to produce an antibody response and may be reassuring that PWH who are appropriately controlled will be appropriate vaccine candidates. Our findings of increased risk for COVID-19 infection in diabetics as evidenced by the presence of antibodies is in keeping with the literature [22]. Furthermore, diabetics are at increased risk of severe disease for multiple reasons, including a compromised innate immunity and the underlying inflammatory state that predisposes to cytokine storm. COVID-19 infection can also lead to worsening glycaemic control. In South Africa only about 60% of all diabetics are diagnosed and less than 10% are well controlled [23]. We do not have data on the presence of co-morbidities in hospitalized patients. However, in view of the interaction between infectious diseases such as tuberculosis, HIV and now COVID-19 it is imperative that increased attention be paid to the detection and management of non-communicable diseases in South Africa. A limitation of the study was that it utilised the Roche Elecsys™ kit, which detects antibodies produced against...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
